Euro Meds Agency Accepts Iveric Application for Avacincaptad Pegol for Geographic Atrophy

 Astellas Pharma US, Inc.  (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Committee for Medicinal Products for Human Use (CHMP) of the EMA will start its review of the MAA under the centralized licensing procedure for all 27 member states of the European Union (EU).

https://www.biospace.com/article/releases/european-medicines-agency-accepts-iveric-bio-s-marketing-authorization-application-for-avacincaptad-pegol-for-geographic-atrophy/